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Abstract
Background: Pancreatic organoid systems have recently been described for the in vitro culture of pancreatic ductal
cells from mouse and human. Mouse pancreatic organoids exhibit unlimited expansion potential, while previously
reported human pancreas organoid (hPO) cultures do not expand efficiently long-term in a chemically defined,
serum-free medium. We sought to generate a 3D culture system for long-term expansion of human pancreas
ductal cells as hPOs to serve as the basis for studies of human pancreas ductal epithelium, exocrine pancreatic
diseases and the development of a genomically stable replacement cell therapy for diabetes mellitus.
Results: Our chemically defined, serum-free, human pancreas organoid culture medium supports the generation
and expansion of hPOs with high efficiency from both fresh and cryopreserved primary tissue. hPOs can be expanded
from a single cell, enabling their genetic manipulation and generation of clonal cultures. hPOs expanded for months
in vitro maintain their ductal morphology, biomarker expression and chromosomal integrity. Xenografts of hPOs
survive long-term in vivo when transplanted into the pancreas of immunodeficient mice. Notably, mouse orthotopic
transplants show no signs of tumorigenicity. Crucially, our medium also supports the establishment and expansion of
hPOs in a chemically defined, modifiable and scalable, biomimetic hydrogel.
Conclusions: hPOs can be expanded long-term, from both fresh and cryopreserved human pancreas tissue in a
chemically defined, serum-free medium with no detectable tumorigenicity. hPOs can be clonally expanded, genetically
manipulated and are amenable to culture in a chemically defined hydrogel. hPOs therefore represent an abundant
source of pancreas ductal cells that retain the characteristics of the tissue-of-origin, which opens up avenues for
modelling diseases of the ductal epithelium and increasing understanding of human pancreas exocrine biology as well
as for potentially producing insulin-secreting cells for the treatment of diabetes.
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Background
The pancreas exhibits dual functions: on the one hand, ac-
inar and ductal cells act as an exocrine organ which aids
in digestion, whilst on the other hand, pancreatic β cells,
which are located in the islets of Langerhans together with
α, δ, ε and PP cells, perform an endocrine function by
regulating blood glucose levels through the secretion of
insulin [1]. Both endocrine and exocrine cells are derived
during development from the ventral and dorsal PDX1+
foregut endoderm, which fuse to give rise to the head,
body and tail of the pancreas. After pancreatic foregut
specification, multipotent progenitors diverge into tip and
trunk progenitors. Tip progenitors differentiate into acinar
cells while bipotent trunk progenitors further give rise to
ductal and endocrine cells [1, 2].
Exocrine pancreas disorders include pancreatic insuffi-
ciency, pancreatitis, pancreas cancer and cystic fibrosis.
Diabetes mellitus is the most common disease of the
endocrine pancreas, leading to aberrant regulation of
blood glucose levels. In the case of Type 1 Diabetes
(T1D), β cells are targeted and compromised by an auto-
immune reaction. Solid pancreas and islet transplants
are the gold standard curative treatments of T1D due to
the restoration of a functional pool of cells. However,
there is a shortage of suitable donor organs for trans-
plantation. Expansion of islets in vitro would be an ideal
treatment strategy; however, this remains a challenge
due to the low proliferative capacity of mature endocrine
cells and the tendency of islets to undergo epithelial to
mesenchymal transition in culture [3]. Notably, ductal
pancreas cells retain some degree of plasticity and can
give rise, in some circumstances, to endocrine cells
in vitro [4–7] and in vivo [8–10]. Therefore, human
ductal cells could serve as a starting material for model-
ling pancreas ductal diseases ex vivo as well as for the
derivation of glucose-responsive insulin-producing cells,
provided they can be efficiently expanded in vitro.
In order for any given cellular source to serve for disease
modelling as well as for a regenerative cell therapy, there
are a number of criteria to fulfil; these include the gener-
ation of a large number of cells and demonstration of their
genetic and transcriptomic stability over time. Addition-
ally, in order for a cell therapy to translate into the clinic,
production under Good Manufacturing Practice (GMP)
conditions with a chemically defined medium, as well as
safety of the product, must be demonstrated. Pluripotent
stem cells (PSCs: either ESCs or iPSCs [11–14]) have
attracted much attention as a source material both for
pancreas disease modelling as well as for cell therapies to
treat diabetes. However, the high mutation rates of PSCs
in vitro and predisposition to form teratomas in vivo,
upon transplantation, warrants concern over the use of
these cells for therapies in the clinic [15, 16]. In contrast,
epithelial organoids derived from adult tissues such as the
liver [17], colon, stomach and prostate [18] exhibit a high
degree of genomic integrity, with very low base substitu-
tion rates in coding regions. Indeed, Whole Genome Se-
quencing (WGS) of clonally expanded human liver
organoid cultures demonstrated that 10-fold fewer muta-
tions arose during long-term expansion of organoids com-
pared with iPSC cultures [17]. Hence, efficient expansion
of adult human pancreatic tissue has the potential to miti-
gate the limitations of ESC/iPSC-derived disease model-
ling and the safety and genetic stability hurdles for cell
therapies, in part because the cells do not have to revert to
a pluripotent-state.
The culture of human primary ductal cells is not triv-
ial, and early studies failed to expand material past 1–2
weeks [4, 19]. Utilising 3D culture techniques, we estab-
lished adult pancreas organoids from mouse pancreatic
ducts that could be expanded long-term in vitro while
also maintaining the capability to undergo endocrine dif-
ferentiation in vivo [20]. Since then, we and others have
adapted the culture system in order to generate adult
human primary pancreas tissue ductal organoids [21–
23]. Despite this success, efficient long-term expansion
of adult human pancreas organoids (hPOs) and their
clonal derivation has yet to be shown. In addition, long-
term expansion from cryopreserved adult tissue, which
would facilitate the cryo-banking of tissue material for
subsequent cellular derivation, has not been achieved.
Here we report the long-term expansion of hPOs from
both fresh and cryopreserved pancreas tissue from human
donors, in a chemically defined, serum-free medium. We
demonstrate their genomic stability in vitro, safety in vivo
and their expansion potential in a chemically defined
hydrogel. Our pancreas organoid model opens up the op-
portunity for establishing protocols for disease modelling
for exocrine disorders as well as highlighting a potential
cellular source for the future development of cell therapies
for endocrine diseases such as T1D.
Results
Generation, long-term expansion and clonal derivation of
human ductal pancreatic organoids
We and others have previously reported culture systems
that support human ductal pancreatic organoid growth
[21–23]. However, these suffer from several shortcom-
ings in their application for disease modelling and cell
therapy: (1) they do not support the long-term expan-
sion required to generate the necessary cell numbers
[22], (2) the medium compositions are not chemically
defined and require the addition of serum to the
medium [21, 23], 3) the extracellular matrix (ECM) used,
namely Matrigel, suffers from batch-to-batch effects and
additionally, is derived from mouse tumours, which
makes it difficult to produce under GMP compliant con-
ditions [21–23]. Hence, we first sought to develop a
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chemically defined medium that would support the
long-term expansion of human primary ductal cells.
Human pancreas tissue samples were obtained from
deceased transplant organ donors, enzymatically
digested and isolated pancreatic ducts were seeded in
Basement Membrane Extract Type 2 (BME 2) as ECM.
A cocktail of growth factors and small molecule inhibi-
tors were tested in different combinations and concen-
trations until we obtained an optimised culture medium
that would support the expansion of human primary
pancreas ductal cells beyond passage 10 (Fig. 1a). After
several iterations to adapt our previously reported mouse
culture conditions [20], we developed an optimised ex-
pansion medium for human pancreatic organoids (hPO-
Opt.EM) by the combined addition of a TGFb inhibitor,
Forskolin (FSK) and Prostglandin E2 (PGE2) together
with an increased concentration of Rspo1. These factors
were tested due to their use in the translation from
mouse to human organoid cultures in other tissues,
namely the liver (TGFb inhibitor and FSK) [17] and
stomach (PGE2) [24]. This optimised serum-free culture
medium supports the generation of hPOs with high effi-
ciency (> 90%) (Additional file 2: Table S1) and facilitates
their long-term expansion beyond 180 days in culture
compared with previously published protocols (Add-
itional file 1: Figure S1a). Isolation of ductal fragments
can be conducted either by handpicking of ducts [23] or
by filtration of the digested tissue. Handpicking of ducts
results in a purer population of ductal organoid struc-
tures at P0; however, filtration is substantially faster
(handpicking > 30min vs. filtration ~ 5min) and yields
more organoids (Fig. 1b). Regardless of the ductal
enrichment technique used, seeded ductal cells begin to
proliferate and rapidly form cystic organoids by day 7,
which are ready to passage by day 14–21 at a split ratio
of (1:4–1:6) (Fig. 1c). Using the optimised medium,
hPOs can be robustly expanded up to at least 6 months
(Fig. 1d,e, Additional file 1: Figure S1a). To date, we have
derived hPO lines capable of long-term expansion from
27 out of 29 healthy human donors (i.e. donors without
any known pancreatic disease) with an age range of
24–79 years. Of note, successful hPO establishment is
independent of the donor’s sex, age or BMI (Additional
file 2: Table S1), while unsuccessful isolations were due to
technical reasons.
While our work was ongoing, a report [22] described
culture conditions that support hPO generation with a
similar efficiency to our optimised media (hPO-Opt.EM)
(Additional file 1: Figure S1b). However, as with previ-
ous studies, the culture medium reported [22] does not
efficiently sustain long-term expansion of hPOs, as they
deteriorate rapidly from P3–4 (Additional file 1: Figure
S1c,d). Using hPO-Opt.EM, the hPOs can be expanded
with high efficiency, exhibiting an initial doubling time
of 78 h which slows to 177 h at later passages (Fig. 1f).
These data indicate that hPOs are capable of the vast
expansion required for both, disease modelling as well as
cellular therapies.
A key benefit of many recent organoid systems is the
ability to cryopreserve organoids at early passages and
then thaw at later timepoints to re-establish cultures. As
expected, the hPO cultures reported here are amenable
to cryopreservation and expandable cultures can be
readily re-established upon thawing (Fig. 1g). The ability
to cryopreserve hPO cultures enables the sharing and
storage of resources, yet it still requires hPO derivation
to be conducted as quickly as possible following sample
collection. By contrast, cryo-banking of primary tissue
would further facilitate the workflow for global collec-
tion and subsequent distribution of tissue world-wide,
including to labs situated at great distances apart. Hence,
we next tested whether hPO cultures could be initiated
from cryopreserved tissue. We first optimised the cryo-
preservation of the fresh tissue and subsequent organoid
derivation from it. Prior to cryopreservation, the primary
tissue was mechanically minced so that upon reconstitu-
tion in the freezing medium the tissue would be more
uniformly suspended and cool in a more homogeneous
manner than one large piece of tissue. The tissue was
then stored at − 80 °C for 3 weeks. Upon thawing, tissue
fragments were washed to remove any remaining freez-
ing medium and subsequent derivation was performed
as with fresh tissue. Organoid derivation efficiency was
on average 10-fold lower from cryopreserved tissue com-
pared with fresh tissue (Additional file 1: Figure S2a,b),
however, in all cases, hPOs were successfully generated
from cryopreserved samples (Fig. 1h, Additional file
1Figure S2a). hPOs generated from cryopreserved tissue
displayed similar expansion efficiencies as cultures de-
rived from freshly isolated pancreata (Additional file 1:
Figure S2c). Using this methodology, donor material can
be collected, cryopreserved and transferred to a recipient
laboratory for derivation without time restrictions.
In addition to the expansion and passaging of orga-
noids upon mechanical dissociation of organoid struc-
tures into fragments (Additional file 1: Figure S2d), our
hPO culture system supports expansion from dissociated
single cell suspensions. The colony formation efficiency
from single hPO cells does not significantly decrease
during long-term culture (Additional file 1: Figure S2e),
and therefore single cells can be isolated at both early
and late passages and cultured to generate expandable
cystic organoids. The ability to expand from single cells
opens up opportunities for genetic studies as well as
genetic manipulation of the cultures. As an example, we
have generated mutant hPOs from single cells following
viral infection with a lentivirus containing a GFP re-
porter. Following viral infection, the cells underwent
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fluorescent cell sorting (Additional file 1: Figure S2f) to
select for successful viral integration and were then
expanded to generate GFP positive hPO cultures
(Additional file 1: Figure S2 g).
In addition, we have generated clonal cultures for
studies of genome integrity by first seeding single cells at
low density, picking out newly formed single organoid
structures and transferring each organoid to a separate
BME 2 drop. The single organoid can then be passaged
to generate hPO cultures of the same clonal origin (Fig.
1i,j). Comparison of the mean variant allele frequency
(VAF) of single nucleotide variants can be used to assess
the clonality of cells. The VAF for three different
cultures derived in this manner from the same donor
was close to 0.5 (Clone 1 = 0.45, Clone 2 = 0.51, Clone
3 = 0.50), suggesting that each of these hPO cultures was
derived from the clonal expansion of a single ductal cell
in vitro (Fig. 1k).
In summary, our optimised hPO culture system
enables the long-term expansion of human primary ductal
pancreas tissue from both fresh and cryopreserved
samples, and even as clonal cultures.
Characterisation of human primary tissue-derived
pancreatic organoids
Pancreatic ducts are single cell-layered structures that
are responsible for the collection and transfer of digest-
ive enzymes produced by acinar cells to the duodenum.
hPOs recapitulate the single cell-layer morphology and
epithelial polarisation of their tissue of origin (Fig. 2a,b).
mRNA expression analysis of hPOs (derived from either
fresh or cryopreserved tissue), isolated primary ducts
and isolated islets (Fig. 2c) reveals that hPOs express in-
creased levels of the adult stem cell marker LGR5 [25].
hPOs, isolated ducts and islets all express similar levels
of the pancreatic progenitor and beta-cell marker PDX1.
We find hPOs express higher levels of the ductal marker
SOX9 in comparison to islets, whilst there is no signifi-
cant difference between hPOs and isolated ducts. These
findings suggest hPOs maintain a pancreatic ductal iden-
tity during in vitro culture. This is further supported as
hPOs and isolated ducts express significantly less insulin
mRNA than islets. It should be noted that some insulin
expression was detected in the ductal preparation. We
hypothesise that this is likely due to an artefact of the
isolation method used for primary ducts, which although
enriches for ductal cells, may also include other contam-
inating acinar and endocrine tissue. Furthermore, we
find hPOs maintain expression of SOX9 and KRT19
(ductal markers) as well as PDX1 at the protein level
during long term culture (Fig. 2d), consistent with the
preservation of ductal identity over months in culture.
Of note, similar expression patterns and tissue architec-
ture were observed from hPOs derived from cryopre-
served tissue as compared to hPOs derived from freshly
isolated tissue (Figs. 2c and Additional file 1: Figure S3a,
b). Therefore, our chemically defined, optimised pancreas
organoid medium supports the long-term expansion of
human pancreatic tissue as ductal epithelial cells from
both fresh and cryopreserved donor tissue (Additional file
1: Figure S2b).
Genomic stability and in vivo safety of hPOs expanded
long-term in culture
Somatic mutations and chromosomal abnormalities ac-
cumulate spontaneously throughout the lifetime of an
individual, and while most are harmless, others act as
driver mutations which increase the likelihood of cell
transformation and tumorigenesis [26]. For accurate dis-
ease modelling as well as use as a cell therapy, it is vital
(See figure on previous page.)
Fig. 1 Human pancreatic organoids (hPOs) expand long-term, even from cryopreserved tissue and are amenable for clonal expansion. a Schematic of
hPO generation and expansion. Pancreatic tissue undergoes enzymatic digestion to release ductal fragments, which are subsequently enriched either
by handpicking or filtration. Pancreas ductal fragments are then embedded in BME 2 as extracellular matrix and overlayed with the hPO-Opt.EM
medium (see methods; hPO-Opt.EM composition). Generated hPOs can be serially expanded by mechanical dissociation. Cryopreservation can be
performed on the primary tissue for derivation at a later time (blue asterisk) or on the established hPOs (black asterisk). b Comparison of P0 cultures
following ductal enrichment by handpicking (left) or filtration (right) (n = 5). c Brightfield images of ductal fragments isolated from fresh human
pancreatic donor tissue grown and expanded as hPOs. d hPOs can be expanded and cultured long-term in vitro. Representative images of hPO
culture at passage 10 (P10). e hPOs can be passaged over many months in hPO-Opt.EM. (n = 4 independent donors; circle = passage). f hPO growth
curves indicate that hPOs expand exponentially even at late passages. Graph represents independent donors (early passage, grey n = 4; late passage,
purple, n = 3), doubling time is indicated (78.1 ± 8.4 h at early passages). g) hPO cultures can be cryopreserved as hPO fragments as described in
methods and re-stablished by embedding the fragments in BME 2 and overlayed with hPO-Opt.EM. hPOs derived from cryopreserved fragments
generate new hPOs with same expansion rate as non-cryopreserved hPOs. Representative image of a P4 culture obtained from a hPO culture
cryopreserved at P0 and kept in liquid N2 for 3 months (n = 9 independent donors). h hPOs can be generated from cryopreserved primary human
pancreatic tissue (see methods for details). Image shows hPOs derived from a pancreas tissue that had been cryopreserved for 3 weeks (n = 3).
i Workflow to generate clonal cultures from single hPO cells which are derived from P0 organoids. j Representative images showing the isolation of a
single hPO cell to form a clonal organoid which can then be then clonally expanded long-term (n = 5 independent donors). k The variant allele
frequency (VAF) of single nucleotide variants was assessed using genome sequencing data from three cultures derived from single cells as described
in i), in all cases the VAF was close to 0.5, confirming clonality of these cultures
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Fig. 2 Human pancreatic organoids (hPOs) expanded long-term recapitulate pancreatic ductal epithelium in vitro. a Representative images of H&E staining
of human pancreatic ductal tissue and hPOs. Note that hPOs (right) expanded in culture retain the single-cell morphology exhibited by the pancreatic
ductal tissue in vivo (left) (n = 6 independent donors). b Representative immunofluorescence staining of F-Actin (yellow) demonstrates that hPOs maintain
the epithelial cell polarity typical of ductal tissue (nuclei counterstained with Hoechst, blue) (n = 6 independent donors). cmRNA expression analysis of key
genes involved in stem cell biology (LGR5), pancreatic fate (PDX1), ductal fate (SOX9) and β-cell function (INS) in hPOs derived from fresh tissue (hPO Fresh,
n ≥ 6), cryopreserved tissue (hPO Cryo, n = 3), isolated primary ducts (n = 4) and isolated islets (n = 4). d Immunofluorescence staining (upper panel) and
quantification of positive cells (lower panels) of nuclear PDX1 (red), cytoplasmic KRT19 (green) and nuclear SOX9 (red) protein in hPOs. Graphs represent
number of positive cells for the corresponding marker (≥7 organoids counted per donor). Graphs show mean ± SEM
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that the cells used do not show an increased susceptibil-
ity to accumulate genetic aberrations upon time in
culture, which could interfere with the conclusions ob-
tained from the disease model or cause tumour forma-
tion in the recipient patient if used as a cell therapy. We
analysed the number of chromosomes in both early- and
late-passage hPOs to evaluate their genomic stability
over time in culture (Fig. 3a). As a positive control, we
analysed the number of chromosomes in human pancre-
atic cancer organoids derived from either Intraductal
Papillary Mucinous Neoplasm or Pancreatic Ductal
Adenocarcinoma cancerous tissues (hPC-org-IPMN and
hPC-org-PDAC, respectively). As expected, we found ab-
normal chromosomal numbers even at early stages in
hPC-org cultures, with more than 50% of the cells exhi-
biting chromosomal numbers greater than 46, with the
most severe chromosomal number changes detected in
organoids derived from the more aggressive PDAC tis-
sue (Fig. 3b,c). In contrast we never detected chromo-
somal numbers greater than 46 in either early- or late-
passage hPOs (Fig. 3a,c). In order to assess whether
hPOs undergo large-scale chromosomal rearrangements
or chromosome loss, we conducted copy-number ana-
lysis on clonal cultures. Whole genome sequencing was
performed on three independently derived clonal cul-
tures to ~35x depth. The allele-specific copy number
analysis of tumours algorithm (ASCAT) [27] was then
used to call copy-number changes. ASCAT makes use of
both read depth and the ratio of heterozygous SNPs to
determine allele-specific copy number. The results reveal
no evidence of large-scale chromosomal differences in
the organoids (Fig. 3d, Additional file 3: Table S2) indi-
cating that large-scale chromosomal defects do not
occur as a consequence of long-term in vitro culture
(Fig. 3c,d).
For a successful cell therapy, cells need to persist long-
term in the body without giving rise to tumorous
growths or teratomas. Previous studies that have per-
formed xenografts using healthy human pancreatic orga-
noid cells have reported a low engraftment efficiency
(12.5% of xenografts resulted in cells that could be re-
covered within the 1 month timepoint, and no xeno-
grafts recovered at later timepoints) [21]. We therefore
tested the ability of our hPOs to engraft and be main-
tained long-term (beyond the reported 1 month limit) as
well as their potential tumorigenicity in vivo. In order to
achieve long-term (3month) engraftment of hPOs in im-
munodeficient mice, we first tested multiple injection
protocols by combining different ECMs, injection sites,
as well as the addition of several growth factors and
media to act as an injection vehicle (Additional file 4:
Table S3). We performed injections using Matrigel (a
commonly used yet ill-defined xenogenic ECM), BME
2 (a variant of Matrigel with a higher tensile strength
and lower batch-to-batch variability) and Glycosil
Hyaluronic Acid (G-HA, a chemically defined ECM).
We had previously found that subcutaneous injections
of healthy ductal organoids do not result in engraftment
(data not shown), and therefore we decided to test the
more vascularised kidney capsule and pancreas capsule
as potential injection sites (Fig. 4a). Following several
iterations, we found that the site of injection had a clear
effect on engraftment success. Initial attempts to engraft
hPO cells using 100% BME 2 in the kidney capsule re-
sulted in poor engraftment (20% of animals) within the
1 month timepoint (Additional file 1: Figure S4a; K-0).
Addition of VEGF, Rho Kinase inhibitor and hPO-
Opt.EM medium as a vehicle for the cells, as well as a
dilution of the ECM to 30%, improved engraftment effi-
ciency after 1 month in the kidney capsule (56%; 5 out of
9 mice) (Additional file 1: Figure S4a and S4b; K-1,K-2,
K-3). Remarkably, we found that injection to the pan-
creas caspule allowed 100% engraftment at 1 month re-
gardless of ECM dilution or vehicle supplementation
with VEGF and hPO-Opt.EM medium (Additional file 1:
Figure S4a and b; P-1,P-2). This led us to further test the
ability of the pancreatic niche to support hPO cell sur-
vival at 3 months; we observed 100% engraftment of cells
when using either Matrigel or the chemically defined G-
HA. Overall, transplants of hPO cells into the pancreas
capsule resulted in 100% engraftment at 1 and 3months
(6/6 and 8/8 mice, respectively) while only 43% of trans-
plants into the kidney capsule could be recovered at 1
month (15 out of 35 mice, Additional file 4: Table S3)
with none surviving past the 1 month timepoint (0 out
of 23 mice) (Figs. 4b, Additional file 1: Figure S4a).
Together these results indicate that mixing cells with
growth factors, dilution of the ECM and injection to the
pancreatic niche have a positive effect on the engraft-
ment capability of hPOs.
We then used our optimised xenograft method (injec-
tion of cells with a vehicle supplemented with growth
factors in 30% Matrigel into the pancreas) to test
whether the engrafted hPOs are indeed derived from the
healthy ductal expanded epithelium or represent a
potential sub-population of transformed cells that have
expanded in culture. Healthy pancreas tissue either does
not express or weakly expresses mucins, whereas
pancreatic cancer is associated with the overexpression
of mucins, for example MUC5AC which is uniquely
expressed in pancreatic cancer and used as a diagnostic
marker [28]. Xenografts of hPOs do not exhibit cellular
transformation at 1 month nor at the latest timepoint
assessed (3 months). The engrafted hPO cells display
ductal morphology, maintaining the single cell-layered,
epithelial organisation characteristic of healthy pancreas
ductal tissue and retain expression of KRT19 (Fig. 4c)
and SOX9 (Additional file 1: Figure S4c). Furthermore,
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after 3 months the engrafted cells do not express the
cancer-specific mucin, MUC5AC (Fig. 4d). As a positive
control we performed xenografts of human cancer hPC-
org-PDAC organoids. Injection of hPC-org-PDAC
resulted in engraftment and subsequent generation of
neoplastic tissue, with ductal cells organised into PanIN
structures reminiscent in morphology of the original
PDAC tumour (Fig. 4c). As expected and as previously
reported for transplanted PDAC-derived organoids [21],
we detected the expression of MUC5AC in the engrafted
cells (Fig. 4d). Thus, the morphology of the engrafted
cells and lack of pancreatic cancer markers indicate that
hPOs do not undergo neoplastic transformation in vivo.
Culture of hPOs with a chemically defined, biomimetic,
ECM
The ability of hPOs to undergo expansion and maintain
genomic stability both in vitro and in vivo makes them a
promising platform for use in basic cellular studies of
human pancreas biology, disease modelling and as a cel-
lular therapy. A vital requirement for in vitro studies
focused on understanding basic principles of human
cellular biology (e.g. cell-cell communication, role of
mechanical and physical forces or intracellular commu-
nication) as well as disease modelling and cell therapy is
the ability to manipulate not only the cells and the
medium, but also the ECM in which the cells are cul-
tured. Furthermore, a requirement for a potential cell
therapy is the ability to expand cells under GMP condi-
tions. However, the majority of current organoid proto-
cols use Matrigel and BME 2, which cannot be
manipulated to change their chemical and/or physical
properties (e.g. stiffness). Additionally, these matrices are
not appropriate for clinical use due to their xenogeneic
origin (Engelbreth–Holm–Swarm mouse sarcoma),
which risks pathogenic contamination and immunogen-
icity complications, as well as batch-to-batch differences,
hindering scalability and reproducibility [29]. Hence, we
aimed to develop a chemically defined, adjustable, scal-
able and biomimetic hydrogel in which hPOs could be
established and expanded.
We found that dextran polymers modified with a pep-
tide containing the RGD cell adhesion motif covalently
crosslinked with hyaluronic acid in the presence of
organoid fragments, in a cell-compatible chemical reac-
tion, supported organoid formation and maintained the
epithelial morphology of the organoids (Fig. 5a). Hyalur-
onic acid was chosen as a crosslinker because it has been
shown to support the undifferentiated state of human
embryonic stem cells in vitro [30]. Importantly, this
hydrogel (DEX-hydrogel) is amenable to digestion by
Dextranase, which facilitates passaging and expansion of
the hPOs (Fig. 5a). Isolated pancreatic ducts seeded in
DEX-hydrogel and cultured with hPO-Opt.EM gave rise
to hPO structures in a comparable manner to BME 2
(Fig. 5b). We were able to expand hPOs and perform
several passages (up to P4) in the DEX-hydrogel culture
system (Fig. 5c,d, Additional file 1: Figure S5a), yet the
these organoids expand more slowly and can only be
passaged at smaller ratios (1:2–1:3; Additional file 1:
Figure S5c) when compared to BME 2 grown hPOs.
Characterisation of hPOs generated with either DEX-
hydrogel or BME 2 showed that both ECMs supported
hPO cultures that expressed similar levels of PDX1
mRNA (Fig. 5e), expressed PDX1 and KRT19 protein
and exhibited similar cell polarisation (Fig. 5f). Of note,
the expression of KRT19 and SOX9 mRNA in hPOs cul-
tured with DEX-hydrogel was 2-fold lower than in hPOs
grown in BME 2 (Fig. 5e), potentially underlying the re-
duced expansion capacity seen with the DEX-hydrogel.
Notably, this chemically defined DEX-hydrogel did not
support expansion of hPOs when using a previously
published medium [22], with initially formed organoids
deteriorating 14 days after seeding and before the struc-
tures could be passaged (Additional file 1: Figure S5b).
In summary, we have developed a chemically defined,
tuneable, reproducible and scalable biomimetic hydrogel
which supports hPO growth and initial expansion
although long-term expansion is yet to be achieved.
Discussion
The human pancreas is a complex organ performing a
variety of diverse tissue functions, from food digestion to
control of glucose homeostasis. This complexity is mir-
rored in the wide array of pancreas diseases which range
from pancreatits to diabetes to pancreatic cancer. Recap-
itulating healthy and diseased pancreas tissue in vitro
has proven challenging due to the lack of robust culture
(See figure on previous page.)
Fig. 3 Human pancreatic organoids (hPOs) expanded long-term in culture maintain chromosomal stability over time. a-b Representative images
of chromosome spreads used for counting from (a) healthy human pancreas derived organoids and (b) pancreas cancer derived organoids
(generated from pancreatic tumour tissue; Intraductal Papillary Mucinous Neoplasm (hPC-org-IPMN) and Pancreatic Ductal Adenocarcinoma (hPC-
org-PDAC). c) Chromosome spreads were prepared and counted from early (P3–5) and late (P10–12) passage cultures. Note that hPOs generated
from healthy donors do not display increased chromosomal counts (above 46) indicating hPOs maintain normal chromosome numbers during
in vitro culture, whilst this is not the case for pancreas cancer organoids, as previously reported [21]. The number of chromosome spreads
counted per condition is detailed above the graph. D) ASCAT copy number plots of three clonal hPO cultures show that hPOs do not exhibit loss
of chromosomes or large structural rearrangements during in vitro culture (clonal expansion of 5weeks). The copy-number state for each chromosome is
shown on the Y-axis, with one allele coloured in red and the other in green. Chromosomes are labelled along the top of the graphs
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methods that would enable the expansion of non-
transformed human pancreas cells while preserving
tissue of origin (healthy or diseased) characteristics.
Recently, organoid culture systems have emerged as a
promising technology to bridge the gap between cell
lines and in vivo tissue [31]. Pancreas organoids derived
from adult mouse pancreatic ducts recapitulate the
ductal epithelium structure and physiology in culture.
However, healthy human pancreas tissue has proven
more challenging to recreate and expand in culture.
Fig. 4 Expanded human pancreatic organoids (hPOs) do not show signs of transformation following long-term engraftment. a Experimental
design. Following hPO generation and expansion with BME 2 and hPO-Opt.EM, hPOs were transplanted into either the kidney capsule or pancreas
capsule of NSG mice; tissues were collected after 1 month or 3months. b Summary of engraftment success after 1 month or 3months for all hPOs
injected, including multiple injection compositions of ECMs and growth factors (for full details please see Table S3 and Fig. S4). c H&E staining
demonstrates survival of hPOs (G-Graft) after 3months in the mouse pancreas (PN-pancreas) and shows engrafted hPOs are formed by a single cell-
layered epithelium (upper middle panel) recapitulating the ductal tissue structure of a healthy pancreatic tissue (upper left panel). Xenografts of
pancreas cancer organoids (hPC-org-PDAC) obtained after 1 month resulted in aberrant ductal morphology reminiscent of the tumour of origin (lower
panels), as expected. The human origin of the engrafted cells in the mouse pancreas is confirmed by expression of human-specific KRT19 (green),
nuclei counterstained with Hoechst (blue) (right panels). d Analysis of primary tissue shows expression of the cancer marker MUC5AC (red) only in
tissue from a PDAC tumour resection and not in healthy tissue (n = 4). Of note, MUC5AC is absent in xenografts from organoids derived from healthy
donors (n = 4), even at 3months, while it is strongly expressed in xenografts derived from hPC-org-PDAC organoids already after 1 month (n = 2)
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Fig. 5 (See legend on next page.)
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While three protocols, including ours, describe the es-
tablishment of human pancreatic ductal organoids
in vitro [21–23], these suffer from a limited capacity for
expansion, use of serum-containing, chemically ill-
defined medium and an inability to generate organoids
from single cells. These limitations hamper their use in
studies of pancreas duct cell biology and genetics as well
as for disease modelling of the exocrine compartment
and potential cell therapy approaches.
While healthy, non-transformed, human pancreas tis-
sue had proven difficult to maintain ex vivo, human pan-
creas organoids derived from tumour tissue [21, 32] or
tumour biopsies [33, 34] have already been established
and utilised for modelling pancreas cancer in vitro and
for identifying drug sensitivities, as these faithfully recap-
itulate the architecture, transcriptome and mutational
landscape of the tumour of origin in a patient-specific
manner. However, other exocrine pancreas diseases,
such as cystic fibrosis or pancreatitis, have not yet been
modelled in vitro due to the lack of a culture system for
manipulating primary human ductal epithelium ex vivo.
In this work we describe an optimised culture system
to enable the long-term expansion of human pancreas
ductal cells as human pancreas organoids (hPOs) in a
chemically defined, serum-free medium, which will
facilitate the development of disease models derived
directly from diseased tissue. Critically, we show that
our hPO medium enables the clonal expansion of
healthy ductal cells, which had previously proved chal-
lenging [4, 19], thus facilitating their genetic manipula-
tion. This holds the potential to promote the
development of in vitro models for exocrine diseases
following step-wise, guided genetic manipulation, as de-
scribed for colon cancer, where the sequential addition
of mutations using CRISPR technology has enabled the
identification of the minimal set of mutations that can
induce colon cancer in healthy human colon cells [35].
This opens up unprecedented opportunities for the
study of developmental lineages as well as mutational
processes in human pancreas tissue, which requires the
study of clonally-derived cells, similar to studies per-
formed in murine systems investigating the clonal
evolution of colon and stomach cells [18, 36].
The ability to recapitulate exocrine diseases of the
ductal compartment in culture, either directly from dis-
eased tissue or after the sequential addition of mutations
to healthy epithelium, would enable their use as plat-
forms to identify treatments for these diseases. On that
front, there have been advances using PSCs (either ESCs
or iPSCs) for disease modelling of exocrine pancreas dis-
eases such as developmental defects [37], pancreas can-
cer [38] and cystic fibrosis [39]. However, the need for
cell reprogramming and subsequent erasure of the cell’s
epigenetic memory prevents modelling of the adult dis-
ease in full, and is particularly limited in recapitulating
the influence of the (epi) genome in terms of disease es-
tablishment and progression. Here, we demonstrate that
our hPOs maintain chromosome stability and do not
undergo transformation during long-term engraftment
in vivo, which makes them a promising system for
disease modelling as well as the genetic manipulation
mentioned above.
One prevalent pancreatic disease that may be treatable
following further development of hPOs is Type 1 Dia-
betes. T1D is caused by a lack of insulin-producing β-
cells in the pancreatic islets. The most common treat-
ment is administration of exogenous insulin, but this
neither cures T1D nor prevents its long-term complica-
tions including heart, kidney and peripheral vascular dis-
eases. Whole pancreas or islet transplantation restores a
therapeutic pool of functional β-cells, which take over
the precise physiological control of blood glucose levels.
Since it is currently not possible to culture and expand
pancreas islets in vitro, only fresh islets are used for
transplantation. However, donor scarcity and the re-
quirement for life-long immune suppression make this
treatment unviable for the majority of patients. Pancre-
atic organoids generated from mouse ducts retained the
(See figure on previous page.)
Fig. 5 A chemically defined Dextran-based hydrogel supports hPO growth. Organoids were derived and expanded from freshly isolated human
pancreas tissue either in standard BME 2 as ECM or in the chemically defined dextran-based hydrogel (DEX-hydrogel). a Schematic showing the
workflow to use DEX-hydrogel as ECM when seeding ductal fragments for hPO culture initiation or organoid fragments during passaging (left panel).
During passaging, dextranase is used to digest the hydrogel and Dextran 6 is added to the culture medium thereafter to prevent hydrogel breakdown
(right panel), see methods for details. b Representative images of hPO cultures derived from freshly isolated human pancreas tissue and initiated in BME 2
(left) or DEX-hydrogel (right). Pictures were taken 21 days after seeding. c-d hPOs can be passaged up to passage 4 when cultured in DEX-hydrogel. Note
that, hPOs in DEX-hydrogel expand to a lesser extent than those with BME 2 and cultures begin to deteriorate after P4. c Representative images of hPOs in
DEX-hydrogel at P3 (n = 3). d Graph represents the expansion potential of independent donors cultured with BME 2 or DEX-hydrogel. (circle = passage,
arrows indicate ongoing cultures, capped lines indicate cultures that deteriorated). emRNA expression analysis of hPO cultures (P1-P4) reveals that
organoids grown with DEX-hydrogel retain the expression of ductal and pancreatic genes although KRT19 and SOX9 are at a lower level than those
cultured with BME 2 (Statistical analysis with paired t-test). f Immunofluorescence staining reveals normal cellular polarisation of hPOs in DEX-hydrogel and
that the protein expression of ductal and pancreatic markers is maintained in DEX-hydrogel compared to BME 2 (F-Actin - yellow; PDX1 - red; KRT19 -
green; Nuclei were counterstained with Hoechst - blue). Experiments were performed in n = 2 independent donors
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ability to differentiate to endocrine lineages; if this can
be replicated in the human, these hPOs may serve as the
basis for expanding a large number of cells, which can
then be differentiated and transplanted into a patient.
We demonstrate that hPOs maintain ductal biomarkers,
therefore endocrine differentiation of the hPOs will be
required in order to act as a cell therapy for T1D and is
the subject of current investigations. There is evidence,
though, that indicates endocrine differentiation of hPOs
could be feasible. Human pancreatic ductal cells have
been reported to become insulin positive as part of the
adaptive increase in beta cell numbers during pregnancy
[40]. Likewise, in vitro, there are suggestions that differ-
entiated ductal cells can be reprogrammed to insulin
positive fates, both in mouse [41] and in human cells
[42, 43]. For a cell therapy, it would be of great benefit
to differentiate the cells without using adenoviral overex-
pression of transcription factors, which could cause gen-
omic alterations. To that end, Loomans and colleagues
have reported a method to prime human pancreatic
ductal cells for differentiation during in vitro culture by
modulation of the culture medium. Upon transplant-
ation into the kidney capsule, these cells could then fur-
ther differentiate into insulin+ cells; however, the cells
could not delaminate from the ductal epithelium to form
bona fide pancreas islets and whether these cells are
glucose responsive remains to be determined [22].
Another important aspect in tissue and disease model-
ling is the ECM, which is a crucial component in all
tissues, and for many organoid systems it provides a
scaffold and physical sites for cells to attach. Interactions
between cells and the ECM have been implicated in
many biological processes, including establishment of
stem cell niches and cellular differentiation. Additionally,
abnormal ECM dynamics are often associated with dis-
ease [44]. Recent advances in the generation of in vitro
organoid systems with ECM have provided a new oppor-
tunity to investigate these interactions; however, the use
of ECMs such as Matrigel and BME 2 is suboptimal due
to their xenogenic origin, inability to modulate the ECM
components and batch-to-batch variability. A fully
chemically defined hydrogel has been shown to be able
to support growth of human intestinal organoids [45]
but as yet, fully chemically defined hydrogels have not
been able to support human liver or pancreas organoid
culture [46]. Here, as a proof-of-principle, we present a
fully chemically defined ECM that can support hPO der-
ivation and culture with a similar morphology compared
to organoids grown in BME 2, and which therefore
could provide a starting point for future biochemical
and physical cell-ECM studies. Due to its chemically de-
fined nature, it also has advantages over Matrigel and
BME 2 in developing a GMP compliant production pro-
cedure. Additionally, the possibility of manipulating the
ECM composition might facilitate the in vitro modelling
of the pathogenic ECM-remodeling often observed in
pancreatic diseases ranging from pancreatitis to pancre-
atic cancer. It should be noted, though, that the hPOs
expand much more slowly in our defined ECM than in
BME 2 (Additional file 1: Figure S5c). Therefore, opti-
misation of the chemically defined hydrogel for long-
term expansion of hPOs is still to be achieved and will
be the subject of future studies.
Our work demonstrates a robust model for the expan-
sion of human pancreatic ductal cells as hPOs, which
maintain cell identity as well as genomic integrity. This
work will pave the way for further studies of epithelial
biology, pancreatic disease modelling, as well as pro-
viding a potential source for a novel diabetes treatment.
Conclusions
hPOs can be expanded long-term, from both fresh and cryo-
preserved human pancreas tissue in a chemically defined,
serum-free medium with no detectable tumorigenicity. hPOs
can be clonally expanded, genetically manipulated and are
amenable to culture in a chemically defined hydrogel. hPOs
therefore represent an abundant source of pancreas ductal
cells that retain the characteristics of the tissue-of-origin,
opening up avenues for modelling diseases of the ductal epi-
thelium and increasing understanding of human pancreas
exocrine biology as well as for producing insulin-secreting
cells for the treatment of diabetes.
Methods
Primary human tissue
Primary pancreas tissue was obtained by the Cambridge
Biorepository of Translational Medicine (CBTM) from
deceased organ donors from whom multiple organs were
being retrieved for transplantation. Pancreas samples
were taken via two routes: from donors during the organ
retrieval operation (in which organs other than the pan-
creas were taken for transplant) or from pancreata which
were initially removed for organ transplantation but
were subsequently declined and allocated for research.
Tissue samples were placed in cold University of
Wisconsin organ preservation solution prior to trans-
portation to the laboratory.
Donor tissue was taken after obtaining written in-
formed consent from the donor’s family for studies ap-
proved by the NRES Committee East of England,
Cambridge South for the Department of Surgery, Uni-
versity of Cambridge, REC reference; 15/EE/0152 and
the NRES Committee East of England - Cambridgeshire
and Hertfordshire Research Ethics Committee for the
Department of Surgery, University of Cambridge, REC
reference; 16/EE/0227. Pancreas cancer tissue was
obtained from patients undergoing pancreatic resection
surgery who had given full written informed consent for
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studies approved by the NRES Cambridgeshire 2
Research Ethics Committee for Human Research Tissue
Bank, Addenbrooke’s Hospital, REC reference; 11/EE/
0011 and NRES Committee London - Westminster Re-
search Ethics Committee for the Department of Surgery,
University of Cambridge, REC reference; 15/LO/0753.
Samples were taken by clinical histopathologists after
gross examination of the resected tissue. Pancreatic islets
were obtained from the Scottish National Blood Trans-
fusion Service (SNBTS) Islet Isolation Center (NRES
West Midlands- South Birmingham Research Ethics
Committee, REC reference; 16/WM/0093).
Isolated primary pancreatic ducts for qRT-PCR ana-
lysis were collected via two methods: either by manual
handpicking of ductal fragments following pancreas tis-
sue digestion (as detailed below) or via surgical dissec-
tion of the main pancreatic duct from the pancreata
allocated for research. Briefly, the common bile duct was
separated from surrounding tissue and followed towards
the ampulla of Vater where it connects to the primary
pancreatic duct. The primary pancreatic duct was then
separated from surrounding tissue and a segment was
isolated.
Generation and culture of hPO
Handling and processing of samples was performed
according to HTA guidelines. To generate organoid cul-
tures, approximately 5 mg of pancreas sample was manu-
ally minced and further dissociated with the gentleMACS
dissociator (Miltenyi Biotec) for a total of 2min. Minced
tissue was washed twice in Wash medium [Dulbecco’s
Modified Eagle Medium (DMEM), high glucose, Gluta-
MAX, pyruvate supplemented (Life Technologies) with
1% Foetal Bovine Serum (FBS) (Life Technologies) and 1%
Penicillin/Streptomycin (10,000 U/mL) (Life Technolo-
gies)] and digested in 40mL of Digestion solution [Colla-
genase Type I (Sigma-Aldrich) and Dispase II (Life
Technologies) at a concentration of 0.125mg/mL in
DMEM containing 0.1mg/mL DNase I (Sigma-Aldrich)]
and placed at 37 °C for 1 to 2 h. Isolated ducts were either
hand-picked with a pipette or the whole digestion mixture
was filtered with a 100 μm pore nylon cell strainer
(Falcon). Ductal fragments were washed in Basal medium
[Advanced DMEM/F12 (Life Technologies) supplemented
with 1% Penicillin/Streptomycin, 1% Glutamax 100x (Life
Technologies), and Hepes (Life Technologies) 10mM]
and spun at 200 g for 5 min. The cell pellet was mixed
with reduced growth factor BME 2-RGF (Basement Mem-
brane Extract Type 2 3533-010-02; AMSBIO, Cultrex),
seeded in a 24 well plate and overlayed with the optimised
hPO expansion medium (hPO-Opt.EM), unless specified
otherwise. BME 2-RGF was used as ECM for all experi-
ments except for those specified in Fig. 5 and Additional
file 1: Figure S5 in which hPOs generated in BME 2-RGF
were compared with those cultured in the chemically de-
fined hydrogel. hPO-Opt.EM composition: [Basal medium
(described above) supplemented with 1X N2 and 1X B27
(both from GIBCO), 1.25mMN-Acetylcysteine (Sigma-
Aldrich), 10% RSPO1 conditioned serum-free media
(homemade as previously described [23]), 10 nM [Leu15]-
Gastrin I human (Sigma-Aldrich), 50 ng/mL EGF (Pepro-
tech), 25 ng/mL Noggin (Peprotech), 100 ng/mL FGF10
(Peprotech), 10mM Nicotinamide (Sigma-Aldrich), 5 μM
A83.01 (Tocris), 10 μM FSK (Tocris) and 3 μM PGE2
(Tocris)]. hPO-Opt.EM was supplemented with 10 μM
Rho Kinase inhibitor (Y27632, Sigma-Aldrich) during
the first 7 days. After 14 days, passaging was per-
formed as previously described [23]. Cryopreservation
of established organoids was conducted as previously
described [23].
Cryopreservation of pancreas tissue
Samples were manually minced and further dissociated
using the gentleMACs dissociator (Miltenyi) for a total
of 2 min. Samples were resuspended in 1 mL Recovery
Freezing medium [(Dulbecco’s Modified Eagle Medium
(High Glucose), fetal bovine serum, and DMSO (10%);
Gibco)] and cryopreserved in a Cell freezing container at
-80 °C. To initiate hPO generation after cryopreserva-
tion, the sample was thawed at 37 °C and washed twice
in Wash medium. The procedure was then conducted as
described above, beginning with the addition of Digestion
solution.
Dispersion of hPOs to single cells
Preparation of single cell mixtures was performed as pre-
viously described [23]; briefly, confluent hPO wells were
collected and washed with cold Basal medium. Cells were
centrifuged at 200 g for 5min and resuspended in 1mL of
pre-warmed trypsin (TrypLE™ Express Enzyme (1X)-Ther-
mofisher). Organoids were pipetted using a narrowed
Pasteur 10 times and incubated for 5min at 37 °C to make
single cells. After incubation, the cells were pipetted 10
times and checked for single cells. Digestion was stopped
by adding cold Basal medium and the digest was filtered
through a 40 μm pore nylon cell strainer (Falcon) to
remove doublets.
Doubling time calculation
Doubling time was calculated as follows; the hPO cul-
tures were dissociated into single cells as described
above. Cell numbers were counted by trypan blue exclu-
sion at the indicated time points. From the basic formula
of the exponential curve y(t) = y0 x e (growth rate x t)
(y = cell numbers at final time point; y0 = cell numbers
at initial time point; t = time) the growth rate was de-
rived. The doubling time was calculated as doubling
time = ln (2)/growth rate for each time window analysed.
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Lentiviral transduction and flow cytometry sorting
hPOs were expanded to passage 3, after which organoids
were made into single cells as described above. 1 × 105
cells were resuspended in virus infection medium con-
taining [CMV-GFP-T2A-Luciferase pre-packaged virus
(Systems Bioscience, Cat. No. BLIV101VA-1) at a multi-
plicity of infection (MOI) of 5 (5x105u/μl) with 1:200
TransDux (System Bioscience) and 1:5 MAX Enhancer
(Systems Bioscience) with hPO-Opt.EM]. The cell sus-
pension was added to a 24 well plate, spun at 32 °C at
600 g for 10 min and then incubated at 37 °C for 6 h.
Cells were then transferred to a 15mL centrifuge tube,
washed twice with Basal Medium and seeded in a 48
well plate with BME 2 and overlayed with hPO-Opt.EM
supplemented with Rho Kinase inhibitor.
After 2 passages, cells were again subjected to a single
cell dissociation as described above. Single cell prepara-
tions, along with negative controls (non-transduced
hPOs) were sorted using a MoFlo cell sorter. GFP+ cells
were seeded into 48 well plates with BME 2 and hPO-
Opt.EM medium (with Rho Kinase inhibitor for the first
7 days). Organoids were expanded for 2 passages and
imaged with the Evos Fl Imaging system (Thermofisher)
for expression of GFP.
Generation of clonal cultures
hPO cultures were initiated from ductal fragments as de-
scribed above, and allowed to grow for 10–14 days. P0
hPOs were made into single cells as described above.
Single cells were centrifuged at 500 g for 5 min, re-
suspended in BME 2 and then seeded in a 48 well plate
at a density of 300–500 cells/well and allowed to expand
for 15–20 days. Individual organoids were then picked
out and reseeded (1 organoid per BME 2 drop). The sin-
gle organoid was allowed to expand and then passaged
as normal [23]. For WGS 2–4 confluent wells (of a 24-
well plate) were collected for each clone, snap frozen in
PBS and submitted for genome sequencing.
Genome sequencing
Cells were lysed using a commercially available kit (Arcturus
PicoPure DNA extraction kit; Thermo Fisher Scientific, ca.
No. KIT0103). The samples were then sent for library con-
struction and paired-end whole genome sequencing (150 bp)
using Illumina XTEN® machines. Sequences were aligned to
the human reference genome (NCBI build 37) using BWA-
MEM. This resulted in a read depth of approximately ~35x
per sample (see Additional file 3: Table S2).
Variant calling was performed using the CaVEMan algo-
rithm [47]. CaVEMan operates using a naive Bayesian
classifier to derive the probability of all possible genotypes
at each analysed nucleotide. For each sample CaVEMan
was run using DNA sequenced from splenocytes from the
same donor as a matched normal to identify germline
SNPs. CaVEMan requires pre-input copy-number options,
which were set to major copy number 5 and minor copy
number 2 for normal clones, as we find this maximizes
detection sensitivity. After variant calling we applied post-
processing filters. We filtered against a panel of un-
matched normal samples to remove single-nucleotide
polymorphisms (SNPs) commonly present in the popula-
tion. We also applied two filters designed to remove map-
ping artefacts associated with BWA-MEM: the median
alignment score of reads supporting a mutation should be
greater than or equal to 140, and below half of these reads
should be clipped. Copy-number changes were called
using the allele-specific copy number analysis of tumours
(ASCAT) algorithm [27]. The same matched normal
sample was used as for calling single nucleotide variants
with CaVEMan.
Culture of hPC
Human pancreas cancer organoids were cultured as previ-
ously described in Boj et al. [21]. Briefly, the tumour sam-
ple was minced and placed in tumour digestion medium
[Collagenase type II (5mg/mL) made up in tumour orga-
noid culture medium (hPC-EM)]. hPC-EM composition:
[Basal medium (described above) supplemented with 1X
N2 and 1X B27 (both from GIBCO), 1.25mMN-Acetyl-
cysteine (Sigma), 10 nM gastrin (Sigma), 50 ng/mL EGF
(Peprotech), 40% Wnt3a conditioned medium (home-
made), 10% RSPO1 conditioned media (homemade), 100
ng/mL FGF10 (Peprotech), 100 ng/mL Noggin (Pepro-
tech), 10mM Nicotinamide (Sigma), 0.5 μM A83.01
(Tocris), 1 μM FSK (Tocris) and 10 μM Rho Kinase inhibi-
tor (Y27632, Sigma Aldrich)] and was digested overnight
at 37 °C. The digest was spun at 300 g for 5min and
washed in Advanced DMEM/F12. The cell pellet was
mixed with reduced growth factor BME 2, seeded in a 24
well plate and overlayed with hPC-EM medium. IPMN-
derived tumour organoids were cultured in hPC-EM while
PDAC-derived organoids were cultured in hPC-EM with
1 μM PGE2 (Tocris).
Chemically defined hydrogel culture
For the chemically defined dextran-based hydrogel
(DEX-hydrogel) used in Fig. 5 and Additional file 1: Fig-
ure S5, SG-Dextran (Cellendes Cat. No. M91–3) and
RGD Peptide (Cellendes Cat. No. 09-P-001) were used
with a thiol-modified hyaluronic acid cross-linker. Thiol-
modified hyaluronic acid was prepared as previously de-
scribed [48], except that 4-(4,6-dimethoxy-1,3,5-triazin-
2-yl)-4-methylmorpholinium chloride (DMTMM, TCI
Chemicals) was used instead of N-(3-dimethylaminopro-
pyl)-N′-ethylcarbodiimide hydrochloride (EDC) and N-
hydroxysuccinimide (NHS) for attachment of cystamine
to hyaluronic acid (Lifecore) with an average molecular
weight of 57 kDa [49]. Additionally, tris (2-carboxyethyl)
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phosphine (TCEP, Sigma-Aldrich, Cat. No. C4706) was
used instead of dithiothreitol (DTT) to reduce the disul-
fide bond of the attached cystamines. Thiol-modified
hyaluronic acid was purified by extensive dialysis against
phosphate buffer at pH 3–5. This procedure yielded a
modification of 12% of the D-glucuronic acid and N-
acetyl-D-glucosamine disaccharides of hyaluronic acid
with thiol groups as determined with the assay as previ-
ously described [50].
For preparation of 50 μl DEX-hydrogel; buffer, water
and SG-Dextran of the SG-Dextran Kit (Cellendes Cat.
No. M91–3) were used; 3 μl buffer (10x CB (pH 7.2)),
12.5 μl Water, 3.4 μl of SG-Dextran (30 mmol/L thiol-
reactive groups) and 2.5 μl of RGD Peptide (20 mmol/L
thiol groups) were combined and incubated for 20 min
at room temperature. Thereafter, 20 μl organoid frag-
ments were added and hydrogel formation was initiated
by adding 8.6 μl of thiol-modified hyaluronic acid (50
nmol of thiol groups). The hydrogel/organoid suspen-
sion was seeded into 24 well plate during the 8 min pre-
gel period and placed in the 37 °C incubator. 30 min
after the initiation of crosslinking, the hydrogels were
overlayed with the appropriate culture medium.
Passaging of organoids grown in DEX-hydrogel was
achieved by first digesting the hydrogels with Dextranase
(Cellendes Cat. No. D10–1) for 30–40 min at 37 °C ac-
cording to the manufacturer’s recommendations. Once
the gel was digested, organoids were fragmented by
passing through a syringe with 27ga needle 3–5 times.
Organoid fragments were washed 4 times with Basal
medium and twice with Basal medium containing 11
mg/mL Dextran 6 (Carl Roth; Cat. No. 7615.1) to re-
move any Dextranase contamination. After the first pas-
sage, hPOs in DEX-hydrogel were cultured with hPO-
Opt.EM medium supplemented with 10mg/mL Dextran
6, acting as a competitive inhibitor to Dextranase, to
inhibit gel degradation from leftover contaminating
Dextranase; fresh medium was applied every day for
3 days post-passaging.
Chromosome counting
Chromosome counting of organoid cells was performed
as previously described [23]. Briefly, 24 h post-passaging,
hPOs were incubated with 0.1 μg/mL KaryoMAX Colce-
mid solution in PBS (Gibco) for 24 h. hPOs were dissoci-
ated into single cells as described above, and were
subsequently incubated in 1 mL of 0.075M KCl (Fisher
Chemicals) at 37 °C for 10 min. Cells were then fixed in
a solution of 3:1 MeOH:Acetic Acid (VWR Chemicals)
which was added dropwise while shaking. After fixation,
the solution was dropped onto Superfrost Microscope
Slides (VWR) for chromosomes to spread. The slide was
then allowed to dry and mounted with Vectashield-Dapi
(Vector Laboratories) and a coverslip.
Quantitative RT-PCR
RNA extraction of all material (organoids and primary
tissue) was performed using an RNA extraction kit (Qia-
gen), and as previously described [23]. A complete list of
the primers used can be found in Additional file 5: Table
S4. All qRT-PCR data is displayed as mean + SEM, with
each data point representing a separate donor line.
Values are given relative to the expression of the house-
keeping gene Hypoxanthine-guanine phosphoribosyl-
transferase (HPRT).
Organoid and tissue fixation and paraffin embedding
Organoids were collected from wells, washed with Basal
medium and fixed in 10% neutral-buffered formalin
(Sigma-Aldrich) for 30–40min on ice. Primary tissue
and xenograft-derived tissue was placed directly into
10% formalin and fixed overnight at room temperature.
Organoids and tissue were then embedded in paraffin as
follows: samples were dehydrated through a series of
graded-ethanol solutions, followed by xylene (Fisher)
and finally embedded in paraffin. Sections were cut at
5 μm thickness and were placed at 60 °C for 2–24 h.
H&E of organoids, primary tissue and xenograft tissue
Paraffin slides were rehydrated with xylene, and then de-
creasing ethanol concentrations (100–50%) and water. Slides
were then immersed in Haematoxylin (Sigma-Aldrich),
washed and dehydrated in increasing ethanol concentrations
(50–100%), a 10 s wash step of Eosin (Sigma) and finally
xylene. The slides were then mounted with DPX mounting
solution (Fisher).
Immunostaining of organoids and tissue sections
Organoids were washed in PBS with 0.05% BSA follow-
ing formalin fixation as described above. Tissue sections
were rehydrated as described above for H&E staining.
Following rehydration, slides were washed with PBS and
subjected to antigen retrieval by heating to 80 °C in 10
mM Sodium Citrate (Sigma), pH 6 for 20 min. Organoids
and sections were incubated with blocking solution [Tri-
ton X100 (1% for nuclear antibodies and 0.1% for mem-
brane and cytoplasmic antibodies), 1% BSA, 2% donkey
serum] for 2 h at room temperature. Primary antibodies
were applied at specified dilutions overnight at 4 °C.
Organoids and tissues were washed with PBS, and ap-
propriate secondary antibodies were applied for 2 h at
room temperature, washed with PBS and nuclei were
counterstained with Hoechst33342 (Molecular Probes,
Life Technologies). Please refer to Additional file 5:
Table S4 for primary and secondary antibody informa-
tion and dilutions.
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Brightfield and confocal imaging
Brightfield imaging of organoids was performed using a
Leica M80 stereo microscope (Leica Microsystems) and
a Leica DMIL LED microscope (Leica Microsystems).
H&E images were taken using a Leica DM400B LED
microscope (Leica Microsystems). Karyotypes and IF
staining were imaged using a SP8 White Light inverted
confocal microscope (Leica Microsystems) or with a
Leica DMI3000 fluorescent inverted microscope (Leica
Microsystems). Optical sections were acquired at 3 μm
intervals. Images were acquired with Leica application
suite X Software and processed using Fiji.
Mouse xenograft studies
All animal experiments were performed in accordance
with UK Home Office regulations (UK Home Office Pro-
ject License number PPL 70/8702 and PPL P57643EBB).
Immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mice which lack B, T and NK lymphocytes [51, 52] were
bred in-house with food and water available ad libitum
pre- and post-procedures. Male and female animals were
used, aged approximately 6–8 weeks (average weight 20 g/
each). Animals were allocated at random to experimental
groups, tissue sections obtained from animals were
processed, stained and analysed without reference to the
identity of the animal groups.
hPO and hPC-org cultures were expanded in order to
inject 5 × 105-1 × 106 cells per mouse. Organoids were
mechanically dissociated as described for normal passa-
ging and resuspended in the appropriate injection
medium as outlined in Additional file 4: Table S3. The
cells were loaded into a 250 μL glass gastight syringe
(Hamilton) with removable 26ga blunt needles (ESSLAB)
for injection into the kidney capsule or custom made
26ga point needles, bevelled at a 60o angle (ESSLAB) for
injection into the pancreas capsule. Mice were anesthe-
tised using isoflurane gas and the left side of the abdo-
men or peritoneal abdomen was shaved and cleaned
with disinfectant. During the procedure, the mice were
kept under anaesthesia and were kept on heat pads at
37 °C. Injections were performed as described below into
the kidney capsule or pancreas capsule. Following the
xenograft procedure, all animals were kept alive for
either 1 or 3 months after which they were humanely
euthanised under terminal anaesthesia by inhalation of
isoflurane. Tissue was then retrieved for further histo-
logical analysis.
Kidney capsule injections
An incision of the skin was made near the anatomical
position of the kidney, the kidney was localised and a
further incision of the abdominal wall was made to
expose the kidney. The kidney was gently pushed out of
the abdomen and kept wet with sterile saline. A small
incision to the kidney capsule was made with a sharp
needle, then 20 μL of the organoid suspension was
injected under the capsule using the blunt needle syr-
inge. A sterile cotton bud was used to apply pressure to
the point of insertion to stop bleeding and prevent cell
leakage. The kidney was then gently placed underneath
the muscle wall. The muscle wall was sutured first using
continuous suturing with 5–0 vicryl sutures and inter-
rupted sutures were used to close the skin layer after-
which 9 mm autoclip wound clips (Harvard Apparatus)
were placed on the skin to keep the sutures intact.
Pancreas capsule injections
An incision of the skin and abdominal wall was made
along the midline of the abdomen to expose the visceral
organs. The pancreas was exposed and kept wet with
sterile saline. Using a sterile cotton bud for traction,
organoids were injected into the tail of the pancreas,
through the parenchyma, and placed between the inter-
lobular space. The cotton bud was then used to stop
leakage by applying pressure for 10–15 s. The pancreas
was gently placed back to the correct anatomical
position and the abdomen wall and skin were sutured
using continuous suturing with 5–0 vicryl sutures.
Statistical analysis
All summary data are presented as mean ± SEM. Statis-
tical tests were performed using Graphpad Prism software
(GraphPad 8.1). Sample size (n) values used for statistical
analyses are provided in the relevant figure legends. Stu-
dent’s two-tailed unpaired t-test (or paired where speci-
fied) was performed to assess differences between two
groups. When performing a t-test, we assumed normality
and equal distribution of variance between groups. Signifi-
cance was set at P < 0.05 for all experiments.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12861-020-0209-5.
Additional file 1: Figure S1. Optimisation of hPO-Opt.EM culture
medium and its expansion potential compared with published pancreatic
organoid culture systems. A) To obtain an optimised medium to support
hPO isolation and growth, incremental changes were made to previously
published protocols. Expansion graphs show the time hPOs survived
in vitro for n = 4 donors in mouse pancreatic organoid (mPO) medium
[20] supplemented with TGFb inhibitor (top graphs) or in our previously
reported medium supplemented with TGFb inhibitor, PGE2 and Wnt-
conditioned medium containing 10% serum [23] (middle graphs) or in
this new optimised, chemically-defined medium (hPO-Opt.EM) containing
TGFb inhibitor, PGE2, FSK and no-FBS (bottom graphs). The ability of the
hPOs to expand is indicated by passaging events (cirlces), arrows indicate
ongoing cultures, capped lines indicate cultures that deteriorated. While
the first two conditions were not able to sustain long-term culture, the
hPO-Opt.EM medium demonstrates a much greater expansion potential.
B-D) Comparison of the hPO-Opt.EM medium to the chemically-defined
hPO medium published by Loomans and colleagues during the course
of this project [22]. Although both media enable the initial gener-
ation of hPOs, the hPO-Opt.EM medium supports long-term culture
to a much greater extent than Medium [22]. B-C) Representative
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images of hPO cultures derived from fresh pancreas tissue using
the the hPO-Opt.EM medium or Medium [22] at B) passage 0 (P0,
8-days post derivation; magnification in lower panels; n = 3), or C)
at Passage 3 (top) and Passage 4 (bottom) in two independent do-
nors. D) Graph shows the expansion potential of hPOs cultured
with the hPO-Opt.EM medium or the medium published by Loo-
mans and colleagues [22] (arrows indicate ongoing cultures, capped
lines indicate cultures that deteriorated). Figure S2. Human pan-
creas organoids (hPOs) can be derived from fresh and cryopre-
served pancreas tissue and are amenable for genetic manipulation.
A) Organoid cultures derived from fresh tissue (left) or tissue cryo-
preserved at the time of collection (right). The organoid formation
efficiency from cryopreserved tissue was reduced, yet in all cases,
cultures exhibited similar expansion rate to hPOs derived from fresh
tissue. Experiments were performed in n = 3 independent donors,
with similar outcomes. Representative images are shown. B) Orga-
noid formation from fresh tissue is more efficient than from cryo-
preserved tissue, the number of organoids formed following the
isolation of ductal fragments from either fresh tissue (253 ± 58 orga-
noids; black circles) or cryopreserved tissue (25 ± 3 organoids; blue
squares) is shown. Ductal fragments were seeded in a 50 μl BME 2
drop and quantified at P0. Data presented as mean ± SEM. C) hPOs
derived from fresh or cryopreserved tissue expand at similar rates
(circle = passage). D) Following mechanical dissociation all organoid
fragments are capable of forming a new organoid (passage). Repre-
sentative images of hPO culture during passaging are shown. E)
The hPO culture system supports expansion from dissociated single
cell suspensions, hPO cultures derived from single cells exhibit simi-
lar colony formation efficiency at early as well as late passages
(n = 4 independent donors). F-G) Genetic manipulation of hPOs.
hPOs were dissociated to single cells at passage 3 and transduced
with a lentiviral vector carrying a GFP reporter gene. Following viral
transduction the single cells formed hPOs and were expanded for 2
passages. F) hPOs were dispersed into single cells again and FACS
sorting was used to select for GFP-positivity. The GFP+ cells were
isolated and expanded as genetically modified hPOs for a further 2
passages. G) Representative images of genetically modified orga-
noids at passage 8 are shown (n = 2). Figure S3. hPOs derived
from fresh and cryopreserved samples expand as a single cell-layer
epithelium of ductal cells and are phenotypically indistinguishable.
Comparison of hPOs derived from A) fresh tissue (collected at P3)
or B) cryopreserved tissue (collected at P2) from the same donor.
Brightfield images (upper panels) indicate that hPO cultures expand
efficiently as cystic structures regardless of whether the original tis-
sue is fresh (A) or cryopreserved (B). H&E stainings reveal that hPOs
derived from cryopreserved tissue maintain the single cell-layer epi-
thelial architecture seen in the original donor tissue and in hPOs
derived from fresh tissue (middle panels). Immunofluorescence
stainings demonstrate that hPO cultures maintain ductal identity
(KRT19 and SOX9), cellular polarisation (F-Actin) and express PDX1
(lower panels) regardless of the original tissue being fresh (left) or
cryopreserved (right). Figure S4. Optimisation of hPO transplant-
ation. A-B) hPOs were transplanted into NSG mice at different sites
using a combination of different vehicles and ECMs, tissues were
retrieved 1 and 3 months after injections. A) Table outlining en-
graftment conditions and engrafment success rates of hPO xeno-
grafts conducted with a combination of injection medium
compositions and injection sites in order to achieve long-term sur-
vival of hPOs in vivo (NT – not tested). B) Representative H&E im-
ages of engrafted hPO cells at 1 month (upper panels) or 3 months
(lower panels) show engrafted cells form ductal-like structures
in vivo (G-graft, PN-pancreas). C) Xenografts of hPOs into the pan-
creas collected after 3 months show the engrafted cells retain
SOX9 protein expression. Figure S5 hPOs cultured in optimised
hPO-Opt.EM medium grow in a chemically defined hydrogel. A-B)
Comparison of hPO cultures in the chemically defined dextran-
based hydrogel (DEX-hydrogel) initiated from freshly isolated ducts
overlayed with either A) hPO-Opt.EM medium or B) the medium
published by Loomans and colleagues [22]. Both media support
the formation of cystic structures, however, organoids in Medium
[22] quickly deteriorated and could not be passaged. In contrast,
organoids formed with the optimised hPO-EM medium could
undergo expansion up to P4, after which they deteriorated. C)
hPOs generated in hPO-Opt.EM medium expand more slowly in
DEX-hydrogel as shown by the longer time taken for the cultures
to reach confluency in order to be passaged than hPOs embedded
in BME 2 (circles-passage events; arrows indicate ongoing cultures,
capped lines indicate cultures that have deteriorated).
Additional file 2: Table S1. Donor Demographics and organoid
derivation success. Table summarising organ donor information including
age range, Body Mass Index (BMI), ischaemic time of tissue, underlying
pathology and success of organoid isolation. All healthy tissue was
procured from deceased organ donors whose organs were retrieved for
transplantation. Diseased tissue was procured from patients having
undergone surgical resection. Pancreatic islets were isolated in the
Scottish National Blood Transfusion Service (SNBTS) Islet Isolation Centre
and were subsequently allocated for research.
Additional file 3: Table S2. Whole Genome Sequencing and Copy
Number analysis of clonally derived hPO cultures. hPOs were expanded
as clonal cultures from the same donor and whole genome sequencing
(WGS) was performed on the three individual clonal cultures at a
sequencing depth of ~35x. The Allele Specific Copy Number Analysis
(ASCAT) algorithm was used to assess clonal number variation in the
clonal cultures and determine existence of large structural variations.
Additional file 4: Table S3. Transplantation of hPOs and hPC-IPMN and
hPC-PDAC organoids in immunodeficient mice. Table summarising infor-
mation for the healthy and cancer-derived organoid cultures transplanted
into NSG mice including donor ID, passage at time of injection, injection
vehicle composition (Condition), number of mice transplanted (Mice Tx),
location of transplant, overall engraftment success and furthest timepoint
of engraftment.
Additional file 5: Table S4. Materials used for experiments. Table
summarising list of antibodies used for immunostaining, kits used, as well
as primers used for quantitative RT-PCR.
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